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Introduction
The serotoninergic hallucinogens evoke profound changes in perception, thought, mood and cognition (Nichols, 2004) . Chemically, these agents are divided in two main classes: a) indoleamines such as lysergic acid diethylamide (LSD), psilocin, psilocybin, N,N-dimethyltryptamine (DMT) and 5-Methoxy-N,Ndimethyltryptamine (5-MeO-DMT) which bind with high affinity to several 5-HT receptors (5-HT-R), namely 5-HT 1A -R 5-HT 2A -R and 5-HT 2C -R and, b) phenylalkylamines such as mescaline and 2,5-dimethoxy-4iodoamphetamine (DOI) which are highly selective for 5-HT 2A -R and 5-HT 2C -R (McKenna and Peroutka, 1989) . The interest in serotoninergic hallucinogens lies in their capacity to model some schizophrenia symptoms by inducing mental states that resemble psychoses, also helping to study brain areas/circuits altered in psychiatric disorders (Vollenweider et al, 1998) . Moreover, some of these agents were marketed in the past (e.g. LSD) as a therapeutic aid in psychoanalysis, and there is a growing interest in their therapeutic use for the treatment of mood and anxiety disorders (Vollenweider and Kometer, 2010) . 5-MeO-DMT is a natural hallucinogen found in a variety of plant preparations (e.g., Virola snuffs) used for religious and recreational purposes (Shen et al, 2010) . 5-MeO-DMT is a potent fast-acting hallucinogen with short duration of action in humans, and induces various physiological and behavioral changes in animal models . 5-MeO-DMT is currently controlled in the United States as a Schedule I hallucinogen by the Drug Enforcement Administration. Like other indoleamine hallucinogens, 5-MeO-DMT shows high affinity for 5-HT 1A -R and 5-HT 2A -R (Sills et al, 1984; McKenna and Peroutka, 1989) and both receptors participate in its behavioral effects actions (Krebs-Thomson et al, 2006; Winter et al, 2000) .
Preclinical and clinical evidence supports that the psychotomimetic action of classical hallucinogens is mainly mediated by their agonistic actions at cortical 5-HT 2A -R (Aghajanian and Marek, 1999; Beique et al, 2007; Gonzalez-Maeso et al, 2007; Nichols, 2004) . Although this is the prevailing view, other findings indicate that 5-HT 1A -R also play an important role in the behavioral effects of indoleamine hallucinogens (Krebs-Thomson et al, 2006; Van den Buuse et al, 2011; Winter et al, 2000) as well as in the mechanism of action of antipsychotic drugs (Bortolozzi et al., 2010; Kargieman et al, 2012; Newman-Tancredi and Kleven 2011) . However, the exact role of 5-HT 1A-R activation in the psychotomimetic actions of indoleamine hallucinogens remains unclear.
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Hence, previous studies showed that psychotropic agents with different mechanism of action, such as the non-competitive NMDA receptor antagonist phencyclidine (PCP) (Kargieman et al, 2007; , the preferential 5-HT 2A -R agonist DOI (Celada et al, 2008) and the non-selective 5-HT 1A/2A -R agonist 5-MeO-DMT (Riga et al, 2014) , markedly disrupted the activity of rodent prefrontal cortex (PFC), increasing pyramidal neuron discharge and reducing low frequency cortical oscillations (LFCO, <4Hz). Classical and atypical antipsychotic drugs reversed these alterations in all cases.
Given the limited knowledge of the brain areas/networks involved in hallucinogen action, the aim of the present study was to assess the effects of 5-MeO-DMT on cortical activity in anaesthetized mice. We used a combination of genetic (5-HT 2A -R knockout mice) and pharmacological approaches to 1) examine the effect of 5-MeO-DMT on LFCO in PFC and primary sensory areas, and 2) examine the role of 5-HT 1A -R and 5-HT 2A -R in the reduction of LFCO evoked by 5-MeO-DMT in the various cortical areas examined.
Materials and Methods

Animals
We used 9-16 week-old male homozygous 5-HT 2A -R knockout mice (referred as KO2A) and wild-type (WT) mice of the same genetic background (C57/BL6). Generation of KO2A strain has been reported elsewhere (Fiorica-Howells et al, 2002) . Animal care followed the European Union regulations (directive 2010/63 of 22/09/2010) and was approved by the Institutional Animal Care and Use Committee. Stereotaxic coordinates were taken from bregma and duramater according to the mouse brain atlas (Franklin and Paxinos, 2008) .
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A C C E P T E D ACCEPTED MANUSCRIPT 5 using a perfusion pump (50-70 mg/kg/h) to maintain a constant level of anesthesia. Recordings of oscillatory activity (local field potential, LFPs) were carried out in the medial PFC (mPFC; AP+2.2 to +2.4, ML-0.2 to -0.4, DV-1.0 to -2.5 below brain surface; coordinates in mm). In most experiments simultaneous recordings of oscillatory activity in the primary somatosensory (S1, AP+0.5, ML+3.0), primary auditory (Au1, AP-2.8, ML+4.2) or primary visual (V1, AP-3.6, ML+2.5) cortices were also performed using epidural electrodes (electrocorticograms, ECoGs). LFP and ECoGs signal were amplified (X 1000 and X2000 respectively) and filtered between 0.1-100 Hz.
After recording stable baseline activity for 5 min, drugs were administered. 5-MeO-DMT (1 mg/kg) was slowly injected followed by saline (in all genotypes) or the antipsychotics HAL (0.6 mg/kg) or RIS (1 mg/kg) in WT mice. Time between injections was 12 minutes. To further evaluate the role of the 5-HT 1A -R on 5-MeO-DMT induced disruption of prefrontal activity, KO2A mice were pretreated (5 minutes after recording stable baseline activity) with saline or the selective 5-HT 1A -R WAY-100635 (0.5 mg/Kg) before 5-MeO-DMT administration. WAY-100635 dose was chosen from the literature owing to its ability to antagonize behavioural effects of 5- MeO-DMT (Halberstandt et al, 2011) .
Intracerebral microdialysis
Extracellular serotonin (5-HT) concentrations were measured by in vivo microdialysis as previously described (Amargós-Bosch et al, 2004) . Briefly, one concentric dialysis probe (membrane 2 mm long) was implanted in mPFC (AP +2.2; ML −0.2; DV −3.4 from skull). Microdialysis experiments were carried out in freely moving mice 20-24 h after surgery. Probes were continuously perfused with aCSF (in mM: NaCl, 125; KCl, 2.5; CaCl2, 1.26 and MgCl2, 1.18) pumped at 1.5 μl/min and containing 1 μM citalopram to prevent 5-HT reuptake. In these conditions, the extracellular 5-HT concentration is representative of the spontaneous Results are given as (mean±SEM). All data were analyzed by Student's t-test or two-way repeatedmeasures analysis of variance (ANOVA), with treatment (or area) and genotype as factors, followed by Newman-Keuls post-hoc test, as appropriate. The level of significance was set at p<0.05.
Results
Characteristics of LFCO in mouse cortical areas
As previously reported (Kargieman et al, 2012) , the power spectra of LFCO in mouse mPFC did not differ between genotypes (WT: 0.054±0.004; KO2A: 0.064±0.004 μV 2 ; n.s Student's t-test; n=40 and 22, respectively). Similarly, there were no differences among genotypes in the power spectra of LFCO in S1 (WT: 0.053±0.007; KO2A: 0.087± 0.019 μV 2 ; n.s Student's t-test; n=11 and 10, respectively), Au1 (WT: 0.041±0.012; KO2A: 0.027±0.018 μV 2 ; n.s Student's t-test; n=11 and 10, respectively) and V1 (WT: 0.065± 0.011; KO2A: 0.073±0.023 μV 2 ; n.s Student's t-test; n=10 and 6, respectively).
Effect of 5-MeO-DMT on LFCO in mPFC of WT and KO2A mice
As reported in rats (Riga et al, 2014) , systemic 5-MeO-DMT administration significantly reduced LFCO in the mPFC of WT mice. Interestingly, 5-MeO-DMT differently reduced LFCO in WT and KO2A mice (WT: from 0.054±0.004 to 0.030±0.002 μV 2 (51.1±2.5% of baseline), n=40; KO2A: from 0.064±0.004 to 0.041±0.004 μV 2 (61.4±3.3% of baseline), n=13). Two-way ANOVA revealed significant effects of 5-MeO-DMT (F(1,51)=120.21; p<0.00001) and genotype (F(1,51)=4.99; p<0.03) with no significant treatment x genotype 
Effect of 5-MeO-DMT in mPFC of KO2A mice: role of 5-HT 1A receptors
Given the differential effect of 5-MeO-DMT in WT and KO2A mice, we examined the potential involvement 
Effects of 5-MeO-DMT on 5-HT release in mPFC and behavioural scores
Basal extracellular concentrations of 5-HT in dialysed samples of mPFC were WT: 14.5±1.8 (n=15); KO2A: 16.2±2.3 (n=11) fmol/30 μl. Non-significant differences between genotypes were found in basal 5-HT concentrations.
The systemic administration of 5-MeO-DMT (1 mg/kg s.c) decreased extracellular 5-HT concentration comparably in the mPFC of WT and KO2A mice ( Figure 3A) . The maximal decreases were to 57.0±7.0% and 43.6±4.9% of baseline for WT and KO2A mice, respectively. Two-way ANOVA revealed a significant effect of 5-MeO-DMT (F(9,99)=8.35; p<0.00001) with no significant effects of genotype and genotype x treatment interaction.
In parallel, 5-MeO-DMT produced a significant increase in the spontaneous HTR rate in WT but not in KO2A mice (from 0.98±0.29 to 4.09±0.66 in WT and from 0.92±0.34 to 0.39±0.15 in KO2A mice after 5-MeO-DMT administration) ( Figure 3B ). Two-way ANOVA showed a significant effect of 5-MeO-DMT (F(1,11)=8.28; p<0.02), genotype (F(1,11)=21.21; p<0.001) and genotype x treatment interaction (F(1,11)=16.41; p<0.002). 
Effects of local 5-MeO-DMT administration on 5-HT release in mPFC
5-HT 1A autoreceptors play a major role in the control of the ascending serotonergic system. Likewise, there is an additional control of serotoninergic activity by postsynaptic 5-HT 1A -R via direct descending inputs from PFC to the raphe nuclei Gabbott et al, 2005; Vazquez-Borsetti et al, 2009 )". Therefore, in order to discriminate the involvement of presynaptic and postsynaptic 5-HT 1A -R in the reduction of 5-HT release induced by 5-MeO-DMT, we locally applied the compound in mPFC by reverse dialysis. The local perfusion of 5-MeO-DMT (30, 100, 300 μM) by reverse dialysis dose-dependently altered the 5-HT concentration differently in the mPFC of WT and KO2A mice ( Figure 3C ). Two-way ANOVA revealed M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 12 significant effects of 5- 198) =5.11; p<0.00001), genotype (F(1,11)=9.27; p<0.02) and genotype x treatment interaction (F(18,198) =3.73; p<0.00001). The lower concentration used (nominal 30 µM) evoked a similar reduction of extracellular 5-HT in WT and KO2A mice. However, higher concentrations clearly discriminated between WT and KO2A mice ( Figure 3C ). Hence, 300 µM 5-MeO-DMT increased extracellular 5-HT to 149.5±22.1% of baseline in WT mice and 100 µM 5-MeO-DMT decreased 5-HT to 38.8±8.1% of baseline in KO2A mice. Two-way ANOVA of normalized AUCs ( Figure 3D ) of the different experimental periods used revealed significant effects of 5-MeO-DMT (F(3,30)=6.17; p<0.03), genotype (F(1,10)=10.17; p<0.01) and genotype x treatment interaction (F(3,30)=5.94; p<0.03).
Antipsychotic drugs reversal of 5-MeO-DMT effect in mPFC of WT mice.
As previously showed in rats (Riga et al., 2014) 
Effect of 5-MeO-DMT on LFCO in sensory cortical areas of WT and KO2A mice.
To examine whether sensory cortical are affected by 5-MeO-DMT, we recorded LFCO in S1, Au1 or V1 using ECoGs. 5-MeO-DMT reduced LFCO in S1, Au1 and V1 (S1: 67.1±4.3%; Au1: 59.3%±4.1%; V1: 67.1±6.8% of baseline) of WT mice, but not in S1 and Au1 of KO2A mice. Interestingly, 5-MeO-DMT reduced LFCO in V1 of KO2A mice (50.2±5.1% of baseline). Figure 5 shows representative examples of the effect of 5-MeO-DMT on LFCO in S1, Au1 and V1 in the two genotypes. In WT mice, two-way ANOVA analysis revealed a significant effect of 5-MeO-DMT (F(1,30)=138.08; p<0.00001), with no effects of area and area x treatment interaction. In KO2A mice, two-way ANOVA analysis revealed a significant effect of 5-MeO-DMT p<0.005). Thus, 5-MeO-DMT disrupts differently S1-LFCO and Au1-LFCO in WT and KO-2A mice. On S1-LFCO two-way ANOVA analysis revealed a significant effect of 5-MeO-DMT (F(1,19) =12.17; p<0.003), genotype (F(2,22)=7.01; p<0.005) and genotype x treatment interaction (F(1,19) =6.18; p<0.03); on Au1-LFCO two-way ANOVA analysis revealed a significant effect of 5-MeO-DMT (F(1,14) =28.95; p<0.0001) and genotype x treatment interaction (F(1,14) =7.88; p<0.02). In contrast, two-way ANOVA analysis of LFCO in V1 revealed a significant effect of 5-MeO-DMT on LFCO (F(1,19) =12.17; p<0.003) with no effects of genotype and genotype x treatment interaction. Post-hoc analysis showed significant differences between 5-MeO-DMT treatment in S1 and Au1 in the two genotypes, but not in V1 ( Figure 5B ). DMT in V1 vs S1 and Au1 (KO2A). WT mice, n=11, 10 and 12 for S1, Au1 and V1, respectively; KO2A mice, n=10, 6 and 9 for S1, Au1 and V1, respectively.
Discussion
The present study confirms and extends previous observations in rat brain, indicating that 5-MeO-DMT decreases LFCO in PFC by stimulating 5-HT 1A -R and 5-HT 2A -R. We also show that this effect is reversed by classical (haloperidol) and atypical antipsychotic drugs (risperidone). Moreover, in addition to PFC, 5-MeO-DMT reduced LFCO in primary sensory areas (S1, Au1 and V1) of WT -yet only in V1 of KO2A micesupporting the involvement of 5-HT 1A -R in the visual alterations induced by 5-MeO-DMT. Overall, these observations shed further light on the neurobiological mechanisms involved in the brain areas/circuits related to psychotic symptoms, such as hallucinations.
Despite the interest of serotonergic hallucinogens as models of schizophrenia symptoms, few studies examined 5-MeO-DMT effects on brain activity (de Montigny and Aghajanian, 1977; Riba et al, 2002) . In recent years, our group has characterized the reduction of LFCO in rodent PFC as a common trait of psychotomimetic agents, including PCP and serotonergic hallucinogens (Celada et al, 2008; Kargieman et al, 2007 Kargieman et al, , 2012 Riga et al, 2014; see Celada et al, 2013 for review). These actions are countered by classical and atypical antipsychotic drugs.
The action of serotonergic hallucinogens has been attributed to the activation of 5-HT 2A -R, for which they show high affinity (Beique et al, 2007; Nichols, 2004; Gonzalez-Maeso et al, 2007; Vollenweider et al, 1998) . However, behavioral studies with WAY-100635 and KO1A mice support the additional involvement of 5-HT 1A -R on the action of indolamine hallucinogens -and in particular 5-MeO-DMT Krebs-Thomson et al, 2006; Winter et al, 2000; Van den Buuse et al, 2011) . In the pre-pulse inhibition (PPI) model, 5-HeO-DMT has opposite effects in rats (decrease; Krebs-Thomson et al, 2006 ) and mice (increase; Halberstadt and Geyer 2011), as observed for selective 5-HT 1A -R agonists (Gogos et al, 2008; Sipes and Geyer, 1995) . Irrespectively of this species difference, the effect of 5-MeO-DMT on PPI was blocked or attenuated by the 5-HT 1A -R antagonist WAY-100635 Krebs-Thomson et al, 2006) , supporting the involvement of 5-HT 1A -R. 5-MeO-DMT reduced LFCO and the BOLD signal in PFC and V1 of the rat. The fall in LFCO was prevented or reversed by selective 5-HT 1A -R and 5-HT 2A -R antagonists (Riga et al, 2014) . Here, we extended the observations to mice and examined the involvement of 5-HT 1A -R and 5-HT 2A -R. Interestingly, 5-MeO-DMT reduced LFCO in the PFC of WT mice, as previously observed in rats (Riga et al, 2014) . It also reduced LFCO in KO2A mice, yet to a smaller extent, which suggests an additional role for other 5-HT-R. Subsequent experiments indicated that WAY-100635 pretreatment prevented the 5-MeO-DMT-induced decrease of LFCO in KO2A mice. Overall, these observations indicate that 5-HT 1A -R and 5-HT 2A -R activation mediates the M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT reduction in LFCO evoked by 5-MeO-DMT. Interestingly WAY-100635 enhanced LFCO in mPFC of KO2A mice but not in WT mice (Kargieman et al, 2012) . The differential effect of WAY-100635 in WT and KO2A mice cannot be ascribed differences in 5-HT 1A -R density (Bortolozzi et al, 2010) . More convincingly, given the high cellular co-expression and interactions between these receptors in PFC (see below), a functional compensatory change in the control of LFCO by 5-HT 1A -R may occur in KO2A mice. 5-MeO-DMT markedly reduced the discharge of 5-HT neurons (de Montigny and Aghajanian, 1977) . Therefore, some of the observed changes might be due to the activation of presynaptic 5-HT 1A -R in the midbrain raphe and the subsequent reduction of 5-HT release in PFC. However, 5-HT 1A -R and 5-HT 2A -R in the mPFC also control serotonergic activity and the local 5-HT release via direct inputs to the raphe nuclei Martín-Ruiz et al, 2001) . These effects are due to the stimulation of 5-HT 1A -R and 5-HT 2A -R in pyramidal neurons (Santana et al, 2004) projecting to the DR (Gabbott et al, 2005; Vazquez-Borsetti et al, 2009 ). Hence, we examined the relative contribution of pre-and postsynaptic 5-HT 1A -R, by comparing the effects of 5-MeO-DMT on 5-HT release in PFC after systemic and local application. As previously observed for PCP, DOI and 5-MeO-DMT in rats (Celada et al, 2008; Kargieman et al, 2007; Riga et al, 2014) , the effects of 5-MeO-DMT were countered by antipsychotic drugs. The reversal by risperidone can be easily explained by direct displacement of 5-MeO-DMT from 5-HT2A-R. However, the M A N U S C R I P T
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reversal by haloperidol needs to be interpreted at network level, since it shows low occupancy of 5-HT2A-R at the dose used (Schotte et al, 1993) . Given the presence of dopamine D2-R in pyramidal and GABAergic neurons of mPFC (Santana et al, 2009) , and their control of excitatory neurotransmission in PFC (Tseng and O'Donnell, 2007) , D2-R blockade by HAL may normalize the excitatory/inhibitory balance altered by 5-MeO-DMT. Thus, antipsychotic drugs with different pharmacological profiles can equally restore the physiological state of LFCO, acting via different signalling pathways and/or cortical networks. Various brain areas involved in the processing of sensory information show an altered activity in schizophrenia patients (Ford et al, 2014) as well as in healthy individuals and rodents treated with serotonergic hallucinogens (Kometer et al, 2011; Riga et al, 2014) . In addition to PFC, 5-MeO-DMT reduced LFCO in S1, Au1 and V1 of WT mice and only in V1 of KO2A mice. Interestingly, the contribution of 5-HT 1A -R to the LFCO reduction differed among the cortical areas examined. Hence, the differential effect of 5-MeO-DMT in WT and KO2A mice was maximal in S1 and Au1, and minimal in V1, suggesting the preferential involvement of 5-HT 2A -R in Au1/S1 and of 5-HT 1A -R in V1.
5-HT 1A -R and 5-HT 2A -R are densely expressed in V1 (Dyck et al, 1993; Jakab et al, 1998) suggesting a central role of these receptors in visual processing. Interestingly, [3H]-5-HT labeled a dense population of 5-HT1 receptors (5-HT1A+5-HT1B+5-HT1D) in layer IVß of the human primary visual cortex (Pazos et al., 1987a) . Similarly 5-HT2 receptors are also expressed in layer IVc in the same area (Pazos et al., 1987b) .
These observations suggest that both receptors are involved in the modulation of thalamic visual inputs from the lateral geniculate nucleus. To our knowledge, there are no similar detailed studies in the visual cortex of the rodent brain. Both receptors inhibit NMDA-induced LTP in visual cortex via different mechanisms (Jang et al, 2015 Kim et al, 2006 . Interestingly, 5-HT 1A -R activation evokes plasticity phenomena in adult rats (Maya-Vetencourt et al, 2011) . Thus, 5-HT 2A -Rs have been implicated in the pathogenesis of visual hallucinations (Ballanger et al, 2010) and both receptors participate in the sensory alterations evoked by psilocybin (Vollenweider et al, 1998; Carter et al, 2007) . Likewise, the marked effect of 5-MeO-DMT in V1 found in the present study is consistent with the changes evoked by this drug on visual processing (de Araujo et al, 2012) . However, the exact reason for the preferential action of 5-MeO-DMT on 5-HT1A-R in V1 is not fully understood.
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18 Pelfort et al, 2012) . This effect could add to the excitatory effects of 5-HT 2A -R activation (Puig et al., 2003) , resulting in a synergistic interaction between both receptors. Thus, the above regional differences may depend on the proportion of 5-HT 2A -R and 5-H 1A -R in pyramidal and GABAergic neurons in the different cortical areas examined.
Conclusions
The present data indicate that the indoleamine hallucinogen 5-MeO-DMT evokes marked alterations in the function of primary sensory areas (Au1, S1, V1) as well as in the highest association cortex (PFC). These alterations are mediated by 5-HT1A-Rs and 5-HT2A-Rs, with a differential contribution of each receptor in the various areas examined. Thus, 5-HT1A-Rs play a major role on 5-MeO-DMT effect on visual and prefrontal cortices. These observations help to elucidate the neurobiological basis of hallucinations.
Moreover, as previously observed with other pychotomimetic agents (PCP, DOI), the fall in LFCO induced by 5-MeO-DMT was countered by antipsychotic drugs, supporting the usefulness of the reversal of psychotomimetic effects on LFCO in antipsychotic drug development. 
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